Companion Diagnostics Market Market By Technology (Polymerase Chain Reaction, Immunohistochemistry, In-situ Hybridization, Next Generation Gene Sequencing, and Others), By Indication (Cancer, Neurological Diseases, Infectious Diseases, and Others), By End
Description
Therapeutic drugs are used in conjunction with a medical instrument known as a companion diagnostic to evaluate how well they function and how they impact a specific human body. Companion Diagnostics and medications are designed to either include or exclude patient groups according to the characteristics of how they react to treatment. This tool helps the doctor decide whether a particular therapeutic plan is best for the patient in the long run.
The FDA approved Roche's Cobas EGFR Mutation Test v2 companion diagnostic in 2021 for use with EGFR tyrosine kinase inhibitors to treat lung cancer. To determine which patients will respond to a therapeutic medication and which ones won't, a clinical test known as Companion Diagnostic (CDx) was developed in tandem with it. This is done to find out which patient groups the matching medication can or cannot treat. By employing CDx to support them in evaluating the benefits, risks, and side effects of therapeutic drugs, practitioners can guarantee patient safety.
These days, it's widely acknowledged that due to advances in genetics and genetic sequencing, different people react to drugs differently. Knowing a person's genetic characteristics, or "biomarkers," can help with the delivery of "the right drug, at the right time, at the right dose, for the right person." Pharmaceutical and biopharmaceutical businesses are always striving to implement patient-selection diagnostic frameworks at the early phases of drug development in order to provide targeted therapies to the right candidate. This contributes to the further expansion of the Companion Diagnostics market.
Companion Diagnostics Market Market based on Connectivity Technology:
The goal of NGS-based symptomatic diagnostics is to enable the use of atomic data from each patient's expanding genome to guide disease treatment choices. Cutting-edge sequencing finds several biomarkers for different pharmacological regimens faster than traditional sequencing approaches. Treatment for a wide range of illnesses may benefit from the use of NGS boards for biomarker testing in a single test. The numerous state-of-the-art advancements in NGS additionally provide market players with a quick benefit over rivals presenting alternative innovations including as PCR, ICH, and ISH. The majority of market rivals are focusing on creating companion demonstration items in light of NGS.
The goal of the next-generation sequencing-based companion diagnostic tests is to open nuclear information from each persistent development genome, thereby coordinating treatment decisions for disease drugs. Front-end sequencing identifies several biomarkers for a variety of drugs faster than other sequencing approaches. Treating a variety of illnesses may be made easier by using NGS sheets for biomarker testing in a single test. Additionally, market organizations benefit from a rapid advantage over rivals offering alternative methods such as PCR, ICH, and ISH because to the numerous inventive degrees of innovation in NGS. As a result, major industry participants are thinking about NGS but focusing on producing graphical items.
The product and service, technology, indication, end user, and region segmentation categories are used to divide the companion diagnostics market. The market is divided into three segments based on Product & Service: Assays, Kits & Reagents, and Software & Services. Moreover, the market is divided into Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, and Other segments depending on technology. Additionally, the market is segmented into five categories based on indication: infectious diseases, cancer, neurological disorders, cardiovascular diseases, and other indications. The market is divided into four segments based on End Users: Contract Research Organizations, Reference Laboratories, Pharmaceutical & Biopharmaceutical Companies, and Other End Users. Furthermore, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa based on region.
The FDA approved Roche's Cobas EGFR Mutation Test v2 companion diagnostic in 2021 for use with EGFR tyrosine kinase inhibitors to treat lung cancer. To determine which patients will respond to a therapeutic medication and which ones won't, a clinical test known as Companion Diagnostic (CDx) was developed in tandem with it. This is done to find out which patient groups the matching medication can or cannot treat. By employing CDx to support them in evaluating the benefits, risks, and side effects of therapeutic drugs, practitioners can guarantee patient safety.
These days, it's widely acknowledged that due to advances in genetics and genetic sequencing, different people react to drugs differently. Knowing a person's genetic characteristics, or "biomarkers," can help with the delivery of "the right drug, at the right time, at the right dose, for the right person." Pharmaceutical and biopharmaceutical businesses are always striving to implement patient-selection diagnostic frameworks at the early phases of drug development in order to provide targeted therapies to the right candidate. This contributes to the further expansion of the Companion Diagnostics market.
Companion Diagnostics Market Market based on Connectivity Technology:
- Polymerase Chain Reaction
- Immunohistochemistry
- In-situ Hybridization
- Next Generation Gene Sequencing
- Others
- Cancer
- Neurological Diseases
- Infectious Diseases
- Others
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- Contract Research Organizations (CROs)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The goal of NGS-based symptomatic diagnostics is to enable the use of atomic data from each patient's expanding genome to guide disease treatment choices. Cutting-edge sequencing finds several biomarkers for different pharmacological regimens faster than traditional sequencing approaches. Treatment for a wide range of illnesses may benefit from the use of NGS boards for biomarker testing in a single test. The numerous state-of-the-art advancements in NGS additionally provide market players with a quick benefit over rivals presenting alternative innovations including as PCR, ICH, and ISH. The majority of market rivals are focusing on creating companion demonstration items in light of NGS.
The goal of the next-generation sequencing-based companion diagnostic tests is to open nuclear information from each persistent development genome, thereby coordinating treatment decisions for disease drugs. Front-end sequencing identifies several biomarkers for a variety of drugs faster than other sequencing approaches. Treating a variety of illnesses may be made easier by using NGS sheets for biomarker testing in a single test. Additionally, market organizations benefit from a rapid advantage over rivals offering alternative methods such as PCR, ICH, and ISH because to the numerous inventive degrees of innovation in NGS. As a result, major industry participants are thinking about NGS but focusing on producing graphical items.
The product and service, technology, indication, end user, and region segmentation categories are used to divide the companion diagnostics market. The market is divided into three segments based on Product & Service: Assays, Kits & Reagents, and Software & Services. Moreover, the market is divided into Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, and Other segments depending on technology. Additionally, the market is segmented into five categories based on indication: infectious diseases, cancer, neurological disorders, cardiovascular diseases, and other indications. The market is divided into four segments based on End Users: Contract Research Organizations, Reference Laboratories, Pharmaceutical & Biopharmaceutical Companies, and Other End Users. Furthermore, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa based on region.
- This report illustrates the most vital attributes of the Companion Diagnostics Market Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Companion Diagnostics Market Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Companion Diagnostics Market Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Companion Diagnostics Market Market.
Table of Contents
146 Pages
- 1. Executive Summary
- 2. Industry Outlook
- 2.1. Industry Overview
- 2.2. Industry Trends
- 3. Market Snapshot
- 3.1. Market Definition
- 3.2. Market Outlook
- 3.2.1. Porter Five Forces
- 3.3. Related Markets
- 4. Market characteristics
- 4.1. Market Overview
- 4.2. Market Segmentation
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. DRO - Impact Analysis
- 5. Technology: Market Size & Analysis
- 5.1. Overview
- 5.2. Polymerase Chain Reaction
- 5.3. Immunohistochemistry
- 5.4. In-situ Hybridization
- 5.5. Next Generation Gene Sequencing
- 5.6. Others
- 6. Indication: Market Size & Analysis
- 6.1. Overview
- 6.2. Cancer
- 6.3. Neurological Diseases
- 6.4. Infectious Diseases
- 6.5. Others
- 7. End-user: Market Size & Analysis
- 7.1. Overview
- 7.2. Pharmaceutical & Biopharmaceutical Companies
- 7.3. Reference Laboratories
- 7.4. Contract Research Organizations (CROs)
- 8. Geography: Market Size & Analysis
- 8.1. Overview
- 8.2. North America (U.S., Mexico, Canada)
- 8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
- 8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
- 8.5. Latin America (Brazil, Argentina)
- 8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
- 9. Competitive Landscape
- 9.1. Competitor Comparison Analysis
- 9.2. Market Developments
- 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
- 9.2.2. Product Launches and execution
- 10. Vendor Profiles
- 10.1. ARUP LABORATORIES
- 10.1.1. Overview
- 10.1.2. Financial Overview
- 10.1.3. Product Offerings
- 10.1.4. Developments
- 10.1.5. Business Strategy
- 10.2. ROCHE MOLECULAR SYSTEMS INC.
- 10.2.1. Overview
- 10.2.2. Financial Overview
- 10.2.3. Product Offerings
- 10.2.4. Developments
- 10.2.5. Business Strategy
- 10.3. DAKO INC.
- 10.3.1. Overview
- 10.3.2. Financial Overview
- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. QIAGEN LTD.
- 10.4.1. Overview
- 10.4.2. Financial Overview
- 10.4.3. Product Offerings
- 10.4.4. Developments
- 10.4.5. Business Strategy
- 10.5. BIOMÉRIEUX INC.
- 10.5.1. Overview
- 10.5.2. Financial Overview
- 10.5.3. Product Offerings
- 10.5.4. Developments
- 10.5.5. Business Strategy
- 10.6. VENTANA MEDICAL SYSTEMS INC.
- 10.6.1. Overview
- 10.6.2. Financial Overview
- 10.6.3. Product Offerings
- 10.6.4. Developments
- 10.6.5. Business Strategy
- 10.7. ABBOTT MOLECULAR INC.
- 10.7.1. Overview
- 10.7.2. Financial Overview
- 10.7.3. Product Offerings
- 10.7.4. Developments
- 10.7.5. Business Strategy
- 10.8. MYRIAD GENETICS INC.
- 10.8.1. Overview
- 10.8.2. Financial Overview
- 10.8.3. Product Offerings
- 10.8.4. Developments
- 10.8.5. Business Strategy
- 10.9. BIOGENEX LABORATORIES, INC.
- 10.9.1. Overview
- 10.9.2. Financial Overview
- 10.9.3. Product Offerings
- 10.9.4. Developments
- 10.9.5. Business Strategy
- 10.10. THERMO FISHER SCIENTIFIC INC.
- 10.10.1. Overview
- 10.10.2. Financial Overview
- 10.10.3. Product Offerings
- 10.10.4. Developments
- 10.10.5. Business Strategy
- 11. Analyst Opinion
- 12. Annexure
- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
- 12.3.1. Data Collation and In-house Estimation
- 12.3.2. Market Triangulation
- 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
